toripalimab + docetaxel + oxaliplatin + leucovorin + 5-FU

This is a drug combination therapy regimen consisting of five agents: toripalimab, docetaxel, oxaliplatin, leucovorin, and 5-FU. Toripalimab is an anti-PD-1 monoclonal antibody, an immunotherapy agent. It is FDA-approved for nasopharyngeal carcinoma (NPC), both as a single agent for recurrent disease and in combination with chemotherapy for first-line treatment of metastatic or recurrent, locally advanced NPC [3][4]. It is also approved in China for various cancers [5]. The chemotherapy components (docetaxel, oxaliplatin, leucovorin, and 5-FU) are established agents used in various cancer treatments. Oxaliplatin plus 5-FU/leucovorin combinations have shown results in colorectal cancer trials [7]. 5-FU works by inhibiting thymidylate synthase, with leucovorin enhancing its efficacy [9]. The provided search results state that this *specific* five-drug combination of toripalimab, docetaxel, oxaliplatin, leucovorin, and 5-FU is not directly mentioned as a standard regimen with established efficacy data. However, similar approaches combining immunotherapy with chemotherapy are being investigated. Without specific clinical trial data on this exact five-drug combination mentioned in the search results, detailed efficacy or safety information for this particular regimen cannot be provided from this source.